Prescribing information



Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1


Over 230,000 brolucizumab injections estimated to have been administered worldwide since launch*2

*The numbers of Beovu units sold since October 2019 until May 2021.2

recommended by nice

reviewed by smc


AMD, age-related macular degeneration; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.


  1. Beovu Summary of Product Characteristics, 2020.
  2. Novartis Data on File. BRODOF21-003, 2021.
  3. National institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at [Accessed 7 June 2021].
  4. Scottish Medicines Consortium. Available at [Accessed 7 June 2021]. 
Rate this content: 
No votes yet
UK | July 2021 | 140363

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at